EN DE
Watch Medinet Group Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Medinet Group Ltd (8161) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Medinet Group Ltd stock HK$0.31, price HK$0.73, that is 57.5% below the price, quality 44 out of 100. Rating: strongly overvalued. Calculated from audited financials with 11 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK

MG Medinet Group Ltd logo Thin data Nov 14, 2026

Medinet Group Ltd

8161 · HK

Far too expensive (fair value 58% below the price) and price moving sideways, but company just good enough: meets 1 of 3 rules.

Follow free in the weekly email
Generates free cash flow 
Quality 44/100 
Price moving sideways (no uptrend) 
Revenue last quarter 18% below a year ago. 
Fair value HK$0.3100 · Strongly overvalued 
Weak Growth (revenue 5y −8.4 %/yr in HKD) 
Loss-making · -3.9% net margin (TTM) 
High debt 
Trails peers (1/11) 
Narrow moat 6/100 · thin data
Thin data 
⚠ Thinly traded
Watch Medinet Group Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$1.85 HK$0.2500 Fair Value HK$0.3100 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range HK$0.2500 – HK$1.85 · fair‑value band HK$0.1700 – HK$0.5400 · the HK$0.7300 price screens above the HK$0.3100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Medinet Group in your weekly email

Every Wednesday you see whether Medinet Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MediNet Group Limited, an investment holding company, provides medical and dental solutions to corporations, insurance companies, and individuals in Hong Kong and the People's Republic of China.

Show moreShow less

It operates MediNet Centre, which offers various medical services, including general practitioner consultation services, immunization services, body checkups, and men's health medical services; and dental clinics, which provide various dental services comprising scaling and polishing, fillings, intra-oral X-rays, routine oral examination, oral health education, preventive dental care, and cosmetic dental treatment, as well as teeth restoration, oral surgery, orthodontics, dentures, veneer, invisalign and implants, and teeth whitening services to self-paid patients.

The company also provides various services, including physiotherapy, Chinese medicine practitioners, vaccination, health assessment, and diagnostic laboratory tests; and specialist services that offer professional solutions.

In addition, it provides online services to sell dental and medical consultation services. The company was founded in 1994 and is headquartered in Causeway Bay, Hong Kong. MediNet Group Limited is a subsidiary of Medinet International Limited.

Stock analysis

Medinet Group Ltd (8161) currently trades at HK$0.7300, while our model-based Fair Value estimate is HK$0.3100, 58% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of HK$0.8300 per share, and 2 of the 11 models we run sit above the HK$0.7300 price.

Bear case: the Asset-Based group reads lowest at HK$0.0800, and 9 of the 11 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$0.1700 (bear) to HK$0.5400 (bull), the price of HK$0.7300 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Medinet Group Ltd reported revenue of HK$83.4M in FY2026 versus HK$121M in FY2022, a compound −8.9%/yr. Reported net income was −HK$3.2M in FY2026.

Key figures

Market cap HK$30.4M (≈ $3.9M) Micro · P/S ratio 0.34 · Net margin −3.9% · Return on equity −34.0% · Return on assets (EBIT) −8.4% (5-year average) · Operating margin −8.3% · Revenue (TTM) HK$83.4M · Revenue growth (YoY) −18.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 59% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −58%, 8161 screens richer than that median.

Fair Value models

Bear HK$0.1700 Fair Value HK$0.3100 Bull HK$0.5400
Price HK$0.7300 · Downside -57.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$0.1600 HK$0.2900 HK$0.5400 77
Growth DCF HK$0.1700 HK$0.3100 HK$0.5300 76
Owner Earnings HK$0.3900 HK$0.6200 HK$1.04 75
All 11 models by family
DCF Models
FCF DCF HK$0.1600 HK$0.2900 HK$0.5400 77
Owner Earnings HK$0.3900 HK$0.6200 HK$1.04 75
5Y Revenue Exit HK$0.0800 HK$0.1900 HK$0.3500 68
5Y EBITDA Exit HK$0.4900 HK$0.9000 HK$1.44 73
10Y Revenue Exit HK$0.1000 HK$0.1900 HK$0.2700 66
10Y EBITDA Exit HK$0.3600 HK$0.6200 HK$0.9100 67
Multiples
EV/EBITDA HK$1.00 HK$1.35 HK$1.69 67
EV/Revenue HK$0.2100 HK$0.3100 HK$0.4100 53
Asset-Based
NCAV (Graham) HK$0.0600 HK$0.0800 HK$0.1200 54
Growth DCF
Growth DCF HK$0.1700 HK$0.3100 HK$0.5300 76
Rev-Margin DCF HK$0.0800 HK$0.2000 HK$0.3400 69

Open the full fair value analysis →

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 27
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 39
Do the profits arrive as real cash?
Financial strength 29
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 66
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 78
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−21.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.4%
Start year 2021 (pandemic). Over 10 years: −1.0% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−0.4% (2021) → −4.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+21.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about +18.8% a year for the price.

8161 screens overvalued: fair value 58% below the price. Compare with HCA Healthcare, Inc →

Compare Medinet Group Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 250 stocks

Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside −57.5% · Bottom 25%
Profitability
Return on assets −8.8% · Bottom 25%
Net margin (12 months) −3.9% · Bottom 25%
Operating margin (12 months) −8.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −18.0% · Bottom 25%
Balance sheet
Debt / equity 2.14× · Highest 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 3.63× · Pricier than median
P/S (12 months) 0.36× · Cheapest 25%
Price / free cash flow (fiscal year) 27.8× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $20.95 $45.53 +117% vs 8161
DaVita Inc DVA $161.79 $218.90 +35% vs 8161
Aier Eye Hospital Group 300015 ¥9.02 ¥10.88 +21% vs 8161
HCA Healthcare, Inc HCA $476.35 $547.34 +15% vs 8161
Tenet Healthcare Corporation THC $271.34 $279.20 +3% vs 8161
The Ensign Group ENSG $182.98 $140.09 −23% vs 8161
Encompass Health Corporation EHC $134.93 $94.81 −30% vs 8161
Fresenius SE FRE €51.78 €34.77 −33% vs 8161
Dr. Sulaiman Al Habib Medical Services Group 4013 207.90 SAR 109.45 SAR −47% vs 8161
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,738 ₹2,908 −67% vs 8161

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medinet Group Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medinet Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8161

Frequently asked questions

Is Medinet Group Ltd (8161) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of HK$0.3100 versus the last price from Nov 6, 2026 of HK$0.7300, about 58% lower (overvalued).
What is the fair value of 8161?
Our model-based fair value for Medinet Group Ltd is HK$0.3100 (as of Nov 14, 2026), built from audited fundamentals. Last price (from Nov 6, 2026): HK$0.7300.
What is the quality score of 8161?
Medinet Group Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medinet Group Ltd (8161)?
We do not set a price target; the yardstick is the fair value of HK$0.3100 (as of Nov 14, 2026) from 11 valuation models. Cautious scenario HK$0.1700, optimistic scenario HK$0.5400. It is a calculation from audited fundamentals, not an analyst target.
What is the Medinet Group Ltd stock forecast for 2026?
Our models put fair value at HK$0.3100, about 58% lower versus the last price from Nov 6, 2026 of HK$0.7300 (overvalued). Cautious scenario HK$0.1700, optimistic scenario HK$0.5400. The calculation is refreshed regularly with new filings.
What is the revenue of Medinet Group Ltd (8161)?
Medinet Group Ltd reported trailing-twelve-month revenue of about HK$83.4M (latest available figure, as of Nov 14, 2026).
What growth is priced into Medinet Group Ltd (8161)?
For today's price to be fair in a discounted-cash-flow model, Medinet Group Ltd would have to grow free cash flow by 21.3 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue fell 8.4 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of 8161 use?
Our models discount Medinet Group Ltd at 9.0 %: a base by market capitalisation (nano), damped by beta 0.46, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Medinet Group Ltd that is +21.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Medinet Group Ltd (8161) delivered so far?
Over the past 5 years revenue at Medinet Group Ltd shrank 8.4 % a year. The price currently implies free-cash-flow growth of +21.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Medinet Group Ltd (8161) growing?
The median revenue growth in the sector is +7.4 % a year. That is the yardstick for the growth priced into Medinet Group Ltd (+21.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Medinet Group Ltd (8161)?
The free-cash-flow yield on the price is 3.60 %: that much free cash flow Medinet Group Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Medinet Group Ltd (8161)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medinet Group Ltd it is HK$0.3100 per share (as of Nov 14, 2026), against a price of HK$0.7300. It is the blended result of 11 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Medinet Group Ltd stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 8161 trades above its calculated fair value: price HK$0.7300, fair value HK$0.3100, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8161?
No. The price is what the market pays today (HK$0.7300); the fair value is what the company's own numbers justify (HK$0.3100). For Medinet Group Ltd the two are HK$0.4200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medinet Group Ltd worth?
The market values Medinet Group Ltd at about HK$30.4M (market capitalisation, as of Nov 14, 2026). Per share that is HK$0.7300; our models calculate a fair value of HK$0.3100 per share.
What do the bullish and bearish scenarios say about 8161?
Our models span a range for Medinet Group Ltd: cautious scenario HK$0.1700, base HK$0.3100, optimistic HK$0.5400 per share (as of Nov 14, 2026, price HK$0.7300). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Medinet Group Ltd (8161)?
Balance-sheet figures for Medinet Group Ltd (as of Nov 14, 2026): return on equity −34.0%, debt of 2.14 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 8161 from its 52-week high?
Medinet Group Ltd trades at HK$0.7300, at its 52-week high of HK$0.7300 and 59% above the low of HK$0.4600 (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.3100 is for.
Which stocks are comparable to Medinet Group Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medinet Group Ltd stock attractive at the current price?
The data as of Nov 14, 2026: price HK$0.7300, calculated fair value HK$0.3100 (−58%), Quality Score 44/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 8161 calculated?
We run Medinet Group Ltd through 11 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of HK$0.3100 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Medinet Group Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medinet Group Ltd (8161)?
The latest price we hold is from Nov 6, 2026 and stands at HK$0.7300. Our model-based fair value is HK$0.3100, about 58% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medinet Group Ltd right now?
The price sits above even our optimistic bull case (HK$0.5400). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (HK$0.1700 to HK$0.5400). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Medinet Group Ltd

How large is the market capitalisation of Medinet Group Ltd (8161)?
The market capitalisation of Medinet Group Ltd is HK$30.4M (≈ $3.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medinet Group Ltd (8161)?
The price-to-sales ratio of Medinet Group Ltd is 0.34 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Medinet Group Ltd (8161)?
The net margin of Medinet Group Ltd is −3.9% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medinet Group Ltd (8161)?
The return on equity (ROE) of Medinet Group Ltd is −34.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medinet Group Ltd (8161)?
On an EBIT basis the return on assets of Medinet Group Ltd is −8.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medinet Group Ltd (8161)?
The operating margin of Medinet Group Ltd is −8.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medinet Group Ltd (8161)?
Revenue at Medinet Group Ltd is down 18.0% versus a year earlier (3y avg −8.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Medinet Group Ltd (8161) carry?
The net debt of Medinet Group Ltd is HK$1.3M (fiscal year 2026, ≈ 1.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Medinet Group Ltd in the live analysis

One click puts Medinet Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.